Why do we care about this research?

Hematological malignancies are traditionally considered to be type of non-refined leision that is not suitable for conventional early interventions such as surgical resection. Recent understandings of disease development suggest that the course of disease progression can be heavily influenced by the body's conditions. An early-intervention therapeutic option my be available by modifying the body's condition to suppress mutant clone expansion.

---

How do we identify the most promising therapeutic strategy for early stages of chronic myeloid malignancies or for high-risk clonal hematopiesis?

Studying Nature-designed clinical trials (genetic Mendelian randomization) + Primate Genome Project comparative analysis + patient sample testing